ArticleFrontiers in bioengineering and biotechnology2022
Efficiency of a Novel Multifunctional Corrosion Inhibitor Against Biofilms Developed on Carbon Steel.
Article in Frontiers in bioengineering and biotechnology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed.
- Long-term continuous corrosion of 316L stainless steel byFrontiers in bioengineering and biotechnology · 2025Article
- 3D Spongin Scaffolds as Templates for Electro-Assisted Deposition of Selected Iron Oxides.Biomimetics (Basel, Switzerland) · 2024Article
- Microbiologically influenced corrosion-more than just microorganisms.FEMS microbiology reviews · 2023Review
- Enhanced antifouling properties of marine antimicrobial peptides by PEGylation.Frontiers in bioengineering and biotechnology · 2023Article
- Enhancing Biocide Efficacy: Targeting Extracellular DNA for Marine Biofilm Disruption.Microorganisms · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
In natural environments, populations of microorganisms rapidly colonise surfaces forming biofilms. These sessile communities comprise a variety of species which contribute to biofouling and microbiologically influenced corrosion (MIC), especially on metals. Species heterogeneity in natural systems confers higher tolerance to adverse conditions such as biocide treatment compared with single species laboratory simulations. Effective chemical treatments to combat recalcitrant biofilms are often dangerous to apply; both to operators and the environment, and face international embargoes. Today, there is a drive to exchange current toxic and environmentally hazardous biocides with less harmful compounds. One effective method of achieving this goal is to generate multi-functional compounds capable of tackling corrosion and biofilm formation simultaneously, thus reducing the number of compounds in dosing procedures. In a previous study, a novel corrosion inhibitor demonstrated biocidal effects against three marine isolates during the early stages of biofilm formation. The compound; CTA-4OHcinn, holds great promise as a multi-functional inhibitor, however its effect on complex, multi-species biofilms remains unknown. Here we evaluate CTA-4OHcinn biocidal capacity against multi-species biofilms developed from oilfield samples. Mature biofilms were developed and treated with 10 mM CTA-4OHcinn for 4 h. The effects of the compound were assessed using mean probable number (MPN), adenosine triphosphate (ATP) quantification, scanning electron microscopy (SEM) and confocal laser scanning microscopy (CLSM). Results demonstrate that CTA-4OHcinn significantly reduces the viability of mature biofilms, supporting previous demonstrations on the secondary function of CTA-4OHcinn as a biocide. CLSM results further indicate that CTA-4OHcinn targets the cell membrane resulting in lysis. This finding complements the established corrosion inhibition function of CTA-4OHcinn, indicating the compound is a true multi-functional organic corrosion inhibitor.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.